Ultragenyx Pharmaceutical (RARE) Shares Outstanding (Weighted Average) (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Shares Outstanding (Weighted Average) data on file, last reported at $100.6 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $100.6 million, up 4.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $100.6 million (up 4.47% YoY), and the FY2025 annual result was $98.6 million, up 8.95% from the prior year.
• Shares Outstanding (Weighted Average) climbed to $100.6 million in Q1 2026 per RARE's latest filing, from $98.6 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $100.6 million in Q1 2026 and troughed at $3.2 million in Q3 2024.
• A 5-year average of $77.8 million and a median of $73.5 million in 2023 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Weighted Average) plunged 95.48% in 2024, then jumped 3012.77% in 2025.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $69.9 million in 2022, then grew by 5.13% to $73.5 million in 2023, then gained by 23.13% to $90.5 million in 2024, then grew by 8.95% to $98.6 million in 2025, then climbed by 2.03% to $100.6 million in 2026.
• Business Quant data shows RARE's Shares Outstanding (Weighted Average) at $100.6 million in Q1 2026, $98.6 million in Q4 2025, and $99.8 million in Q3 2025.